Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Anemia 38Neoplasms 26Breast Neoplasms 4Multiple Myeloma 2Leukemia 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Red-Cell Aplasia, Pure 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Esophageal Neoplasms 1Carcinoma 1

Interventions

ibrutinib 6pirtobrutinib 2blinatumomab 2tozasertib 1ofatumumab 1oblimersen 1obinutuzumab 1mocetinostat 1lucatumumab 1forodesine 1fenebrutinib 1enzastaurin 1Mitoxantrone 1Epoetin Alfa 1Bendamustine Hydrochloride 1Antineoplastic Agents 1ARQ531 12-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Lymphoid × Epoetin Alfa × Clear all
NCT00270049 2011-05-18

Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
195 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Leukemia, Lymphoid, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡